Vanda Pharmaceuticals Management
Management criteria checks 3/4
Vanda Pharmaceuticals' CEO is Mihael Polymeropoulos, appointed in May 2003, has a tenure of 20.83 years. total yearly compensation is $4.27M, comprised of 19.1% salary and 80.9% bonuses, including company stock and options. directly owns 2.17% of the company’s shares, worth $4.86M. The average tenure of the management team and the board of directors is 6.3 years and 4.4 years respectively.
Key information
Mihael Polymeropoulos
Chief executive officer
US$4.3m
Total compensation
CEO salary percentage | 19.1% |
CEO tenure | 20.8yrs |
CEO ownership | 2.2% |
Management average tenure | 6.3yrs |
Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Feb 15Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Feb 13Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement
Feb 10News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts
Nov 11One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be
May 12Vanda Pharmaceuticals: What The Recent Partnership Entails
Oct 06Vanda Pharma, OliPass collaborate to develop oligonucleotide-based therapeutics
Sep 29Vanda Pharmaceuticals Q2 Earnings Preview
Aug 02Vanda Pharmaceuticals: Strong Pipeline Developments To Power Long-Term Upside
May 17Vanda: A Dual Growth And Value Player
Apr 11Analysts Are More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be
Feb 27Vanda: A Prudent Business With Upsides
Dec 30An Intrinsic Calculation For Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Suggests It's 32% Undervalued
Nov 01Is There An Opportunity With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) 47% Undervaluation?
Jun 28It's Unlikely That The CEO Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Will See A Huge Pay Rise This Year
Jun 03This Insider Has Just Sold Shares In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Mar 04CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | US$3m |
Sep 30 2023 | n/a | n/a | US$12m |
Jun 30 2023 | n/a | n/a | US$15m |
Mar 31 2023 | n/a | n/a | US$16m |
Dec 31 2022 | US$4m | US$815k | US$6m |
Sep 30 2022 | n/a | n/a | US$6m |
Jun 30 2022 | n/a | n/a | US$11m |
Mar 31 2022 | n/a | n/a | US$18m |
Dec 31 2021 | US$6m | US$769k | US$33m |
Sep 30 2021 | n/a | n/a | US$34m |
Jun 30 2021 | n/a | n/a | US$32m |
Mar 31 2021 | n/a | n/a | US$32m |
Dec 31 2020 | US$3m | US$746k | US$23m |
Sep 30 2020 | n/a | n/a | US$19m |
Jun 30 2020 | n/a | n/a | US$114m |
Mar 31 2020 | n/a | n/a | US$117m |
Dec 31 2019 | US$4m | US$721k | US$116m |
Sep 30 2019 | n/a | n/a | US$122m |
Jun 30 2019 | n/a | n/a | US$28m |
Mar 31 2019 | n/a | n/a | US$22m |
Dec 31 2018 | US$4m | US$700k | US$25m |
Sep 30 2018 | n/a | n/a | US$13m |
Jun 30 2018 | n/a | n/a | US$1m |
Mar 31 2018 | n/a | n/a | -US$5m |
Dec 31 2017 | US$6m | US$675k | -US$16m |
Compensation vs Market: Mihael's total compensation ($USD4.27M) is above average for companies of similar size in the US market ($USD1.46M).
Compensation vs Earnings: Mihael's compensation has been consistent with company performance over the past year.
CEO
Mihael Polymeropoulos (63 yo)
20.8yrs
Tenure
US$4,269,410
Compensation
Dr. Mihael H. Polymeropoulos, M.D., founded Vanda Pharmaceuticals, Inc. in 2003. He serves as Chairman of The Board at Vanda Pharmaceuticals Inc since June 2021 and has been its Chief Executive Officer, Pr...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 20.8yrs | US$4.27m | 2.17% $ 4.9m | |
Senior VP | 11.3yrs | US$1.44m | 0.093% $ 207.2k | |
Senior VP | 5.6yrs | US$1.50m | 0.040% $ 88.6k | |
Senior VP & Chief Marketing Officer | 4.6yrs | US$1.62m | 0.086% $ 193.6k | |
Senior Vice President of Business Development | 7yrs | US$1.47m | 0.54% $ 1.2m | |
Chief People Officer | 4.6yrs | no data | no data | |
Head of Corporate Affairs | no data | no data | no data |
6.3yrs
Average Tenure
53yo
Average Age
Experienced Management: VNDA's management team is seasoned and experienced (6.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 20.8yrs | US$4.27m | 2.17% $ 4.9m | |
Lead Independent Director | 18.3yrs | US$317.08k | 0.12% $ 266.0k | |
Independent Director | less than a year | no data | no data | |
Independent Director | 4.4yrs | US$296.24k | 0.017% $ 38.9k | |
Independent Director | 4.1yrs | US$279.99k | 0.021% $ 46.8k | |
Independent Director | 4.4yrs | US$294.06k | 0.022% $ 50.3k |
4.4yrs
Average Tenure
66.5yo
Average Age
Experienced Board: VNDA's board of directors are considered experienced (4.4 years average tenure).